Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma
- Compare the survival of patients over 60 with glioblastoma multiforme treated with
standard radiotherapy vs hypofractionated radiotherapy vs chemotherapy.
- Compare the quality of life (QLQ-C30) of these patients.
- Compare the safety, tolerance, and toxicity of these regimens.
- Assess the pharmacoeconomic cost of these regimens.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients undergo standard radiotherapy 5 days a week for 6 weeks.
- Arm II: Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
- Arm III: Patients receive oral temozolomide on days 1-5. Treatment repeats every 4
weeks for up to 6 courses in the absence of disease progression or unacceptable
After completion of study treatment, patients are followed periodically.
Allocation: Randomized, Primary Purpose: Treatment
Duration of survival
Didier Frappaz, MD
Centre Leon Berard
United States: Federal Government